Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00538070 · ClinicalTrials.gov registry record · NA
A Study of the Effects of Sarcosine on Symptoms and Brain Glycine Levels in People With Schizophrenia
A NA study of Schizophrenia, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 68
- Enrollment target
- 2
- Study locations
NCT00538070 is a NA study of Schizophrenia that has completed, run by Massachusetts General Hospital. The registered enrollment target is 68 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (69% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00538070, a NA study of Schizophrenia, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 68 participants
- Enrollment target
- 2
- Study locations
Study Summary
The NMDA receptor has been identified as having a role in substance use disorders as well as in schizophrenia. One example of the former is nicotine's effect on dopaminergic activity not only by increasing the release of dopamine in the Midbrain reward centers, but also through less direct mechanisms affecting alpha-7 nicotinic receptors, NMDA receptors, and Glycine, a co-agonist for the NMDA receptors. In terms of schizophrenia, it has been hypothesized that NMDA receptor hypofunction plays a role in the mechanism for negative symptoms and cognitive dysfunction in these patients. The NMDA hypofunction may be reversed with increased synaptic glycine availability. Sarcosine, or n-methyl-glycine, is a GlyT-1 and System A transport inhibitor actions which could be expected to increase the availability of glycine, in the synaptic space. Sarcosine is a dietary supplement which could be found in several food items such as egg yolks and turkey. Our collaborative team has developed a novel, non-invasive magnetic resonance spectroscopy (MRS) technique for measuring brain glycine changes that allows us to study glycine homeostasis. The purpose of this study is to explore the effect of sarcosine (n-methyl-glycine) on brain glycine concentrations. It is our hypothesis that oral sarcosine, at a dose of 2 grams per day, will be well tolerated and associated with increased brain glycine concentrations. It is our secondary exploratory hypothesis that increases in brain glycine will be associated with behavioral signs of increased NMDA and dopamine activity. This modulation could have future therapeutic potential for disorders of hedonic and cognitive function.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Sarcosine
Study Locations (2)
Massachusetts
- McLean Hospital, Brain Imaging Center - Belmont
- MGH Center for Addiction Medicine - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2007-08 |
| Est. Completion | 2012-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00538070
The ClinicalTrials.gov registry entry for NCT00538070 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (69% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Sarcosine is the first listed.
NCT00538070 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00538070 about?
NCT00538070 is a clinical study titled "A Study of the Effects of Sarcosine on Symptoms and Brain Glycine Levels in People With Schizophrenia". The NMDA receptor has been identified as having a role in substance use disorders as well as in schizophrenia. One example of the former is nicotine's effect on dopaminergic activity not only by increasing the release of dopamine in the Midbrain reward centers, but also through less direct mechanism...
What is the current status of trial NCT00538070?
This trial is currently completed. It is a NA study. The enrollment target is 68 participants. The study started on 2007-08. Estimated completion is 2012-07.
What conditions does trial NCT00538070 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00538070?
The interventions under investigation include: Sarcosine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00538070?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00538070 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.